Online inquiry

IVTScrip™ mRNA-Human AKR7A2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK19579MR)

This product GTTS-WK19579MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AKR7A2 protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001320979.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 8574
UniProt ID B4DZX4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AKR7A2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK19579MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK27839MR IVTScrip™ mRNA-Human ATAD3B, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ATAD3B
GTTS-WK17558MR IVTScrip™ mRNA-Human AMPD2, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMPD2
GTTS-WK18412MR IVTScrip™ mRNA-Human ALG12, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALG12
GTTS-WK12482MR IVTScrip™ mRNA-Human ACYP1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACYP1
GTTS-WK25090MR IVTScrip™ mRNA-Human ASAH1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASAH1
GTTS-WK17532MR IVTScrip™ mRNA-Human ALOX5, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALOX5
GTTS-WK15726MR IVTScrip™ mRNA-Human ALKBH5, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALKBH5
GTTS-WK21458MR IVTScrip™ mRNA-Human AMPD2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMPD2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW